UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 2, 2024

 

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		001-38677		38-3661826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

 

(973) 691-2000

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

—————----

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VTAK	NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2):

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 8.01 Other Events.

 

On March 29, 2024, Catheter Precision, Inc. (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”).   The Consent of Independent Registered Public Accounting Firm dated March 29, 2024 and filed as Exhibit 23.1 to the Form 10-K made reference to Registration Statement on Form S-3 333-269491, and to Registration Statement on Form S-3 Amendment No.1 No. 333-270919, instead of making reference to Registration Statements on Post-Effective Amendment No. 1 to Form S-3 on Form S-1 333-269491 and 333-270919.  A new Consent of Independent Registered Public Accounting Firm, dated April 2, 2024 (the “Revised Consent”), has revised the references to such registration statements accordingly, is attached as Exhibit 23.1 to this Current Report on Form 8-K, and is hereby filed with the SEC. The Revised Consent does not change any previously reported financial results or other disclosure contained in the Form 10-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.		Description
23.1		Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	CATHETER PRECISION, INC.
Date: April 2, 2024	By:	/s/ Margrit Thomassen
		Margrit Thomassen Interim Chief Financial Officer

 

3